ASAS is not a Mendelian/monogenic disorder; there is no causal gene, and heritable connective-tissue/aortopathy genes (e.g., FBN1, TGFBR1/2, COL3A1) contribute only indirectly by predisposing to the aortic pathology that can cause it.
UNANIMOUS
INTEGRATED
genetic_factor
| Provider | Stance | Score | Evidence |
|---|
| falcon |
CONCORDANT |
85% |
No causal gene list for ASAS exists in the retrieved primary sources.
Falcon states ASAS is a vascular syndrome, not typically monogenic, with no causal gene list.
|
| openscientist |
CONCORDANT |
90% |
No causal genes, pathogenic variants, or chromosomal abnormalities are directly responsible. It is an acquired vascular condition.
OpenScientist agrees ASAS is acquired with no causal genes, and adds the indirect predisposing genes (FBN1, TGFBR1/2, COL3A1, ACTA2).
|
Both providers converge on "not monogenic"; OpenScientist alone enumerates the predisposing aortopathy/thrombophilia gene context.
There is no ASAS-specific pharmacotherapy or randomized trial evidence; management is supportive and extrapolated from the precipitating cause — hemodynamic/perfusion optimization (MAP augmentation), CSF drainage, antithrombotic therapy, and intensive rehabilitation.
UNANIMOUS
INTEGRATED
treatment
| Provider | Stance | Score | Evidence |
|---|
| falcon |
CONCORDANT |
88% |
There is no high-quality ASAS-specific randomized trial base; management is typically extrapolated from vascular neurology and the precipitating cause.
Falcon states the lack of ASAS-specific trials and reports supportive management frequencies (antiplatelet 68%, anticoagulation 8%, BP augmentation, lumbar drain).
|
| openscientist |
CONCORDANT |
85% |
Treatment is largely supportive and empirical.
OpenScientist agrees there is no disease-specific pharmacotherapy and details MAP augmentation, CSF drainage, anticoagulation, and rehabilitation. Emphasis differs from Falcon on antithrombotic choice (Falcon: antiplatelets predominate; OpenScientist: heparin/anticoagulation prominent), a coverage difference rather than a contradiction.
|
Divergence in antithrombotic emphasis is contextual (OpenScientist's "heparin most commonly used" is drawn from a COVID-19 SCI series), so scored as concordant on the overall supportive strategy rather than contradictory.
Overview
Both providers frame Anterior Spinal Artery Syndrome (anterior cord syndrome) as an acquired vascular myelopathy caused by ischemia in the anterior spinal artery territory, which supplies the anterior two-thirds of the spinal cord. They converge on the same clinical picture, imaging signature, and management posture, differing mainly in depth: Falcon centers on the diagnostic/perioperative-prevention framing drawn from spinal cord infarction and aortic-surgery literature, while OpenScientist is broader and adds quantitative epidemiology/outcomes, a fibrocartilaginous-embolism and pediatric arm, and a detailed molecular ischemia-reperfusion cascade.
Agreement
Strong concordance on the core concepts: ASA-territory anatomy with dorsal column sparing and dissociated sensory loss; predominantly vascular etiology led by aortic pathology (dissection, atherosclerosis, surgical repair); the acute triad of bilateral motor paralysis, pain/temperature loss, and autonomic dysfunction; hyperacute onset reaching nadir within hours; the pencil-like/owl's eye/snake-eye DWI-restriction MRI signature; poor and severity-dependent prognosis with ASIA A/B as the dominant predictor; the absence of a causal gene (not monogenic); and supportive, non-disease-specific management (perfusion optimization, CSF drainage, antithrombotics, rehabilitation). Both also independently cite ~3.1/100,000 person-year incidence and SCI at ~1-2% of strokes.
Divergence
OpenScientist contributes material Falcon does not: quantitative outcomes (~22% in-hospital mortality, 57% wheelchair dependence), the ASAS ontology identifiers (MONDO/MeSH/SNOMED/DOID), an explicit fibrocartilaginous-embolism and pediatric phenotype, naturally occurring canine/equine disease, and a granular molecular ischemia-reperfusion cascade (NF-κB, NLRP3, HMGB1, ferroptosis, pyroptosis) with named preclinical neuroprotective agents. Falcon uniquely details protocolized aortic-surgery spinal cord protection bundles (MAP/Hb targets, staging, CSF drainage) and TEVAR-like murine models. The only quantitative discrepancies are minor (time-to-nadir upper bound; antithrombotic emphasis) and do not amount to contradictions.
Integration
Promote the concordant backbone into kb/disorders/Anterior_Spinal_Artery_Syndrome.yaml: ASA-territory ischemia pathophysiology with anterior horn/tract injury and dorsal column sparing; the vascular/aortic etiology; the acute motor/dissociated-sensory/ autonomic phenotype; hyperacute onset and the noncompressive MRI signature as diagnostic anchors; poor severity-dependent prognosis (ASIA A/B); the non-monogenic genetic statement; and the supportive treatment strategy.
Not integrated (leads)
The detailed molecular ischemia-reperfusion cascades and preclinical neuroprotective agents (anti-HMGB1, CaMKII inhibition, ferroptosis/pyroptosis modulators) are retained as research leads pending human evidence, as are provider-specific extras such as the aortic-surgery prevention-protocol numbers, veterinary/comparative biology, and the ontology identifier crosswalk.
Cross-provider synthesis comparing the falcon (diagnostic/perioperative-prevention focused) and openscientist (comprehensive, 15-domain) deep-research reports for Anterior Spinal Artery Syndrome. No direct contradictions were found; divergence is coverage/recency and quantitative granularity. best_matching_text values are verbatim excerpts from the two report files; literature evidence snippets are intentionally left to the main curation pipeline pending fetch-reference verification.